BioMarin Pharmaceutical | BMRN - Equity Capital And Reserves

Stock Price
56.18
Daily Change
-0.03 -0.05%
Monthly
-7.72%
Yearly
0.52%
Q2 Forecast
53.83

BioMarin Pharmaceutical reported $6.09B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Bayer EUR 25.95B 3.75B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025